Evidence map›Paper›PMID 26080459›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2015

In vitro and in vivo study on the effect of antifungal agents on hematopoietic cells in mice.

Maria Samalidou, Dimitris Bougiouklis, Timoleon-Achilleas Vyzantiadis, Joseph Meletiadis, Nikolaos Monokrousos, Eleni Siotou, Afroditi Sivropoulou, Achilles Anagnostopoulos, Damianos Sotiropoulos

Open access · greenAbstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Maria SamalidouDepartment of Hematology and BMT Unit, "George Papanicolaou" Hospital, Thessaloniki 57010, Greece Department of Genetics, Development and Molecular Biology, School of Biology, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece msamalidou@yahoo.gr.
Dimitris BougiouklisDepartment of Hematology and BMT Unit, "George Papanicolaou" Hospital, Thessaloniki 57010, Greece.
Timoleon-Achilleas VyzantiadisFirst Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Joseph MeletiadisClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens 12462, Greece.
Nikolaos MonokrousosDepartment of Biological Applications and Technology, University of Ioannina, Ioannina 45110, Greece.
Eleni SiotouDepartment of Hematology and BMT Unit, "George Papanicolaou" Hospital, Thessaloniki 57010, Greece.
Afroditi SivropoulouDepartment of Genetics, Development and Molecular Biology, School of Biology, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Achilles AnagnostopoulosDepartment of Hematology and BMT Unit, "George Papanicolaou" Hospital, Thessaloniki 57010, Greece.
Damianos SotiropoulosDepartment of Hematology and BMT Unit, "George Papanicolaou" Hospital, Thessaloniki 57010, Greece.
G. Papanikolaou General Hospital · GRAristotle University of Thessaloniki · GRNational and Kapodistrian University of Athens · GRUniversity of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liposomal amphotericin B, voriconazole, and caspofungin are currently used for systemic and severe fungal infections. Patients with malignant diseases are treated with granulocyte-colony stimulating factor (G-CSF) for the recovery of granulocytes after chemotherapy or hematopoietic cell (HC) transplantation. Since they have a high incidence of fungal infections, they inevitably receive antifungal drugs for treatment and prophylaxis. Despite their proven less toxicity for various cell types comparatively with amphotericin B and the decrease in the number of leukocytes that has been reported as a possible complication in clinical studies, the effect of liposomal amphotericin B, voriconazole, and caspofungin on HCs has not been clarified. The present study aimed to examine the in vitro and in vivo effect of these three modern antifungals on HCs. Colony-forming unit (CFU) assays of murine bone marrow cells were performed in methylcellulose medium with or without cytokines and in the presence or absence of various concentrations of liposomal amphotericin B, voriconazole, and caspofungin. In the in vivo experiments, the absolute number of granulocytes was determined during leukocyte recovery in sublethally irradiated mice receiving each antifungal agent separately, with or without G-CSF. In vitro, all three antifungal drugs were nontoxic and, interestingly, they significantly increased the number of CFU-granulocyte-macrophage colonies in the presence of cytokines, at all concentrations tested. This was contrary to the concentration-dependent toxicity and the significant decrease caused by conventional amphotericin B. In vivo, the number of granulocytes was significantly higher with caspofungin plus G-CSF treatment, higher and to a lesser extent higher, but not statistically significantly, with voriconazole plus G-CSF and liposomal amphotericin B plus G-CSF treatments, respectively, as compared with G-CSF alone. These data indicate a potential synergistic effect of these antifungals with the cytokines, in vitro and in vivo, with subsequent positive effect on hematopoiesis.

Indexed as

Amphotericin BAnimalsAntifungal AgentsCaspofunginDose-Response Relationship, DrugEchinocandinsFemaleFlow CytometryGranulocyte Colony-Stimulating FactorGranulocytesHematopoietic Stem CellsLipopeptidesMiceMice, Inbred C57BLVoriconazoleAmphotericin BAntifungal AgentsCaspofunginEchinocandinsGranulocyte Colony-Stimulating FactorLipopeptidesliposomal amphotericin BVoriconazolecaspofungincell culturegranulocyteshematopoiesisliposomal amphotericin Bvoriconazole

Identifiers

PMID26080459
PMCPMC4935346
OpenAlexW2239520686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.